Market
Primary focus of public scrutiny from Pfizer trial documents by end of 2025?
2
Resolution / Starting Odds
Vaccine efficacy data • 25%
Adverse side effects • 25%
Trial participant demographics • 25%
Regulatory approval process • 25%
Analysis and reports from major news outlets and public statements from health organizations
Story
U.S. Judge Orders FDA to Release More Pfizer COVID-19 Vaccine Trial Documents for Transparency
Dec 6, 2024, 09:24 PM
A U.S. District Judge Mark Pittman has ordered the FDA to release an additional million pages of documents from Pfizer's COVID-19 vaccine trials. This decision comes after the FDA's unsuccessful attempt to end a public records lawsuit, which sought transparency on the authorization of the vaccines. The court's order aims to provide greater public access to the data behind the vaccine's authorization, following previous efforts to expedite the release of such documents. The documents in question were initially sought to be hidden by the FDA, marking a significant win for transparency.
View original story
Similar markets
No significant impact • 25%
Increased transparency and trust • 25%
Legal challenges against FDA • 25%
Policy changes in vaccine approval • 25%
FDA's Handling • 25%
Vaccine Safety • 25%
Effectiveness of Vaccines • 25%
Data Transparency • 25%
FDA • 25%
Pfizer • 25%
No major impact on any organization • 25%
Public Health Organizations • 25%
Increased trust in vaccines • 25%
Indifference • 25%
Increased demand for transparency • 25%
Decreased trust in vaccines • 25%
76-100% • 25%
51-75% • 25%
26-50% • 25%
0-25% • 25%
Mainstream Media • 25%
Government Agencies • 25%
Pfizer • 25%
Independent Researchers • 25%